# Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptor

Source: https://onco.cc/trials/nct06840821/  
OnCo record `nct06840821` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in triple-negative breast cancer, run by Mainline Biosciences (Shanghai) Co., Ltd, now recruiting.

## Summary

Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors is a phase 1/2, interventional study registered as NCT06840821 by Mainline Biosciences (Shanghai) Co., Ltd, with a registry enrolment figure of 156 participants, started 2025-05-08 and due to reach its primary completion in 2028-07-04. Interventions recorded: MB0151 for injection. Conditions listed: Advanced Solid Tumors. Triple-negative eligibility wording from the registry: "The subject must have a solid tumor confirmed by histology or cytology, and belong to one of the following categories: 1) locally advanced or metastatic SCLC, which has received standard treatment in the past and developed progress or intolerance; 2) Low-grade, medium-grade or high-grade locally adv". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06840821
- Phase: 1/2
- Setting: A Phase I/II, Multicenter, Open-label, Single-arm, Dose-escalation and Dose-expansion Study Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 Sequential Therapy in Adult Subjects With Advanced Solid Tumors (Including Gastroenteropancreatic Neuroendocrine Neoplasms, Small Cell Lung Cancer or Triple Negative Breast Cancer)
- Sponsor: Mainline Biosciences (Shanghai) Co., Ltd
- Enrolled: 156

## Sources

- ClinicalTrials.gov NCT06840821: https://clinicaltrials.gov/study/NCT06840821

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06840821.json